EGFR and neoplasm: In this regard, we recently used the anti-EGFR CL4 aptamer to decorate cisplatin-loaded PNPs and proved the tumor-targeting, safety profile, and anti-tumor activity of the resulting nanovectors in mice bearing EGFR-positive TNBC.